UT Medical School at Houston - Internal Medicine, Division of Oncology, 6410 Fannin Street, Houston, TX 77030, USA.
The efficacy of sequential everolimus (RAD001, Afinitor®), an orally administered inhibitor of mammalian target of rapamycin (mTOR), is one of the therapeutic options in patients with advanced renal cell cancer (RCC). The purpose of this review is to discuss the mTOR pathway and to update current knowledge of the role of everolimus in metastatic RCC.
The function of mTOR and its inhibition, the early development trials of everolimus, the Phase II trial that lead to the Phase III study and ultimately to FDA approval are all discussed in this review. Literature utilized for this review consists of PUBMED for both description of the mTOR pathway and its role, in addition to publications using everolimus in RCC.
Everolimus is currently the only agent with a proven progression-free survival improvement for patients who progressed on a vascular endothelial growth factor receptor-tyrosine kinase inhibitor. Future studies may further shed light on the most optimal use of everolimus.
Written by:
Amato R. Are you the author?
Reference: Expert Opin Pharmacother. 2011 May;12(7):1143-55.
doi: 10.1517/14656566.2011.571382
PubMed Abstract
PMID: 21470068
UroToday.com Renal Cancer Section
